Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan

Clinical Therapeutics

Volumn 32, Issue 7, 2010, Pages 1294-1303

  Hsiang, Kuo Wei ^a   Chen, Tseng Shing ^a,b   Lin, Hsiao Yi ^a,b   Luo, Jiing Chyuan ^a,b   Lu, Ching Liang ^a,b   Lin, Han Chieh ^a,b   Lee, Kuei Chuan ^a,b   Chang, Full Young ^a,b   Lee, Shou Dong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Clinical upper GI events; Cyclooxygenase (COX) 2 inhibitors; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CIMETIDINE; CLOPIDOGREL; ESOMEPRAZOLE; ETODOLAC; ETORICOXIB; FAMOTIDINE; LANSOPRAZOLE; MELOXICAM; MISOPROSTOL; NABUMETONE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; RANITIDINE; STEROID; TICLOPIDINE; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DRUG SAFETY; DUODENUM PERFORATION; DYSPEPSIA; EPIGASTRIC PAIN; FEMALE; FOLLOW UP; GASTRIC ULCER BLEEDING; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HEARTBURN; HEMATEMESIS; HEMATOCHEZIA; HUMAN; INCIDENCE; MALE; MELENA; NAUSEA; PRESCRIPTION; RISK FACTOR; TAIWAN; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIC ULCER; PROSPECTIVE STUDIES; PYRAZOLES; PYRIDINES; RISK FACTORS; SULFONAMIDES; SULFONES; TAIWAN;

EID: 77955250524     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.07.005     Document Type: Article

References (23)

1. Schnitzer TJ Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol. 2006, 25(Suppl 1):S22-S29.
2. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008, 16:137-162.
3. Barozzi N, Tett SE Gastroprotective drugs in Australia: Utilization patterns between 1997 and 2006 in relation to NSAID prescribing. Clin Ther. 2009, 31:849-861.
4. Hashash JG, Atweh LA, Saliba T, et al. Acute NSAID-related transmural duodenitis and extensive duodenal ulceration. Clin Ther. 2007, 29:2448-2452.
5. Gabriel SE, Jaakkimainen L, Bombardier C Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991, 115:787-796.
6. Chan FK, Graham DY Review article: Prevention of nonsteroidal anti-inflammatory drug gastrointestinal complications-review and recommendations based on risk assessment. Aliment Pharmacol Ther. 2004, 19:1051-1061.
7. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomized double-blind comparison. Lancet 1999, 354:2106-2111.
8. Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2000, 43:370-377. Rofecoxib Osteoarthritis Endoscopy Multinational Study Group.
9. Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: A Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007, 5:818-828.
10. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002, 347:2104-2110.
11. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: Results of a randomized double-blind trial. Gastroenterology. 2004, 127:1038-1043.
12. Lai KC, Chu KM, Hui WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med. 2005, 118:1271-1278.
13. Cheng HC, Chang WL, Yeh YC, et al. Seven-day intravenous low-dose omeprazole infusion reduces peptic ulcer rebleeding for patients with comorbidities. Gastrointest Endosc. 2009, 70:433-439.
14. Luo JC, Chang FY, Lin HY, et al. The potential risk factors leading to peptic ulcer formation in autoimmune disease patients receiving corticosteroid treatment. Aliment Pharmacol Ther. 2002, 16:1241-1248.
15. Luo JC, Chang FY, Chen TS, et al. Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy. Br J Clin Pharmacol. 2009, 68:252-259.
16. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000, 343:1520-1528. VIGOR Study Group.
17. Luo JC, Lin HY, Chang FY, et al. Occurrence of peptic ulcer disease in connective tissue disease patients associated with xerostomia. Aliment Pharmacol Ther. 2003, 17:217-224.
18. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Longterm Arthritis Safety Study. JAMA. 2000, 284:1247-1255.
19. Tannenbaum H, Bombardier C, Davis P, Russell AS An evidence-based approach to prescribing nonsteroidal anti-inflammatory drugs. Third Canadian Consensus Conference [published corrections appear in J Rheumatol. 2006;33:440 and J Rheumatol. 2006;33:829]. J Rheumatol. 2006, 33:140-157. Third Canadian Consensus Conference Group.
20. Chan FK, Abraham NS, Scheiman JM, Laine L Management of patients on non-steroidal anti-inflammatory drugs: A clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol. 2008, 103:2908-2918. First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
21. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998, 338:727-734. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.
22. Yeomans ND, Tulassay Z, sz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998, 338:719-726. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.
23. Vergara M, Catalan M, Gisbert JP, Calvet X Meta-analysis: Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther. 2005, 21:1411-1418.